Lisata Completes Marea Acquisition and $225M PIPE, Reshaping Ownership
LSTA sits 49% above its 52-week low of $0.988 on light trading volume (0.4× avg).
Summary
Lisata Therapeutics completed its acquisition of Marea Therapeutics and raised $225 million in a concurrent private placement, with Marea equityholders now controlling 59.54% of the combined company. The deal brings two late-stage cardioendocrine drug candidates and extends cash runway into 2028.
Key Events · M&A and Partnerships · LSTA
-
Marea Acquisition Completed
Lisata acquired Marea Therapeutics on September 17, 2026, issuing 1,793,129 common shares and 211,365.213 Series C Preferred shares (convertible into 1,000 common shares each) to Marea stockholders.
-
$225M Concurrent Private Placement
Lisata sold 150,867.995 Series C Preferred shares at ~$1,491.37 per share (~$1.4914 per common share on as-converted basis), raising approximately $225 million from leading life sciences investors including RA Capital, Forbion, and Third Rock Ventures.
-
Ownership Transformation
Post-transaction ownership: pre-transaction Lisata stockholders hold 2.39%, Marea equityholders hold 59.54%, and PIPE investors hold 38.07% on a fully-diluted, as-converted basis. Total capitalization is ~396,315,542 shares.
-
New Leadership Appointed
Josh Lehrer, M.D. (Marea's CEO) appointed President and COO of Lisata; Ted W. Love, M.D. (Marea's Chairman) appointed to the Board. David Mazzo remains CEO.
Analysis · LSTA · Life Sciences
Lisata Therapeutics has closed its acquisition of Marea Therapeutics and secured a $225 million private placement, fundamentally transforming the company. Pre-transaction Lisata stockholders are diluted to just 2.39% of the combined entity, while Marea equityholders hold 59.54% and PIPE investors hold 38.07%. The deal brings two late-stage cardioendocrine assets — MAR001/005 for severe hypertriglyceridemia and MAR002 for acromegaly — with topline data expected in Q4 2027. The $225 million financing is projected to fund operations into 2028. This is a reverse merger in substance: Marea's pipeline and leadership now dominate the company, with Josh Lehrer (Marea's CEO) becoming President and COO and Ted Love joining the board. The transaction requires stockholder approval for the Series C Preferred conversion, which will be sought at an upcoming meeting.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 40.7% of the 381 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LSTA was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.99 to $5.07. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.